Amylyx Q2 Loss Widens on Legal Costs; Five Insiders Adopt 10b5-1 Plans Ahead of Key Phase 3 Data
AMLX has more than doubled off its 52-week low of $7.48.
Summary
Amylyx missed Q2 estimates with a $0.39 loss per share as legal and pre-launch costs surged. Five insiders adopted 10b5-1 plans to sell up to 395,000 shares. Cash runway extends into 2028, but all eyes are on the upcoming Phase 3 avexitide data.
Key Events · Earnings and Guidance · AMLX
-
Q2 Loss Misses Estimates
Net loss of $43.4M ($0.39/share) vs. $41.4M loss a year ago, missing the $0.36 consensus. SG&A surged 40% to $21.9M on legal settlement costs and pre-commercialization spending.
-
Cash Reserves Decline
Cash, equivalents, and marketable securities fell to $250.8M from $317.0M at year-end 2025. Management expects runway into 2028.
-
Insider Selling Cluster
Five insiders — including both Co-CEOs, the CFO, the CLO, and a director — adopted new 10b5-1 plans authorizing sales of up to 395,000 shares total. Plans were adopted between April 9 and May 11, 2026.
-
Class Action Settlement Progresses
Court preliminarily approved the $6.5M settlement of the Shih securities class action, with a final approval hearing set for September 10, 2026. A significant portion is covered by insurance.
Analysis · AMLX · Life Sciences
Amylyx posted a larger-than-expected Q2 loss of $0.39 per share, missing consensus by $0.03, as SG&A costs jumped 40% to $21.9 million — driven by the $6.5 million class action settlement and pre-commercialization spending for avexitide. Cash reserves fell to $250.8 million, still funding operations into 2028. The quarter also saw five insiders, including both Co-CEOs and the CFO, adopt new 10b5-1 trading plans authorizing sales of up to 395,000 shares. This cluster of insider selling plans, combined with the earnings miss and rising expenses, raises concerns about management's near-term outlook — especially with pivotal Phase 3 LUCIDITY data for avexitide expected in Q3 2026, a binary event that will define the company's future.
At the time of this filing, AMLX was trading at $21.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $7.48 to $22.28. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.